Why the study?
Ventricular septal defect after acute myocardial infarction has high mortality, and no randomized controlled trials exist to guide optimal treatment strategy.
This clinical consensus statement provides state-of-the-art guidance on managing ventricular septal defects post-myocardial infarction, an area currently lacking randomized trial evidence.
No RCTs guide post-MI VSD treatment; leaves optimal strategy open pending randomized data.
Ventricular septal defects are a rare complication after acute myocardial infarction with a mortality close to 100% if left untreated. However, even surgical or interventional closure is associated with a very high mortality and currently no randomized controlled trials are available addressing the optimal treatment strategy of this disease. This state-of-the-art review and clinical consensus statement will outline the diagnosis, hemodynamic consequences and treatment strategies of ventricular septal defects complicating acute myocardial infarction with a focus on current available evidence and a focus on major research questions to fill the gap in evidence.
No takes yet. Share an insight, caveat, or question.
Schlotter et al. (2024) conducted a review in Ventricular septal defects complicating acute myocardial infarction. Surgical or interventional closure vs. Untreated was evaluated on Mortality. Ventricular septal defects complicating acute myocardial infarction have a mortality close to 100% if untreated, and surgical or interventional closure remains associated with very high mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: